ArticleFrontiers in medicine2026
Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Combined allergic rhinitis and asthma syndrome (CARAS) is a prevalent chronic respiratory disorder among children, characterized by the coexistence of allergic rhinitis and asthma symptoms, thereby substantially impairing quality of life. Pediatric Tuina, a traditional Chinese manual therapy, has demonstrated potential in the management of pediatric respiratory conditions; however, its effectiveness in treating CARAS remains insufficiently studied. Objective: This trial aims to assess the clinical efficacy and safety of pediatric Tuina in the treatment of CARAS, with the objective of establishing an effective, safe, and convenient external therapy of traditional Chinese medicine for CARAS. Methods: A total of 92 children aged 6-14 years with CARAS in remission will be randomly assigned (1:1) to either the control group (conventional medication) or the intervention group (conventional medication plus pediatric Tuina). The intervention will be administered three times weekly for 4 weeks, followed by a 24-week follow-up. The primary outcome measure is the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) score. Secondary outcomes include the Childhood Asthma Control Test (C-ACT) / Asthma Control Test (ACT) score and traditional Chinese medicine (TCM) symptom scores. Safety will be assessed by monitoring any adverse events during the treatment period. Discussion: This study will provide evidence for the efficacy and safety of pediatric Tuina in improving CARAS symptoms and quality of life in children. Clinical trial registration: https://itmctr.ccebtcm.org.cn/mgt/project/view/1966089236985806848, identifier [ITMCTR2025001712].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.